Stem cell company ReNeuron will move its operations and headquarters to Cardiff, UK after leasing an R&D and manufacturing facility from the Welsh government.
Despite the director’s resignation, the US NIH Intramural Center for Regenerative Medicine (CRM) has not closed and will hold a workshop to guide the direction of the center’s future, the NIH told us.
Scientists at the University of Nottingham have created a new combination of hydrogels that allows dense tissue structures to be produced from human pluripotent stem cells (HPSC) in a single step process never achieved before.
Catalent Pharma Solutions has agreed with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to advance one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.
GE Healthcare has launched a new cell culture medium that it claims will let manufacturers skip lengthy validation steps and achieve greater batch to batch consistency.
Biopharma desire to speed up the extraction and freezing process necessary for the safe transport of cell-based regenerative medicines is driving demand for cryopreservation reagents, according to biologics CDMOs.
Tokyo, Japan-based JCR Pharmaceuticals has asked UK firm Plasticell to help develop differentiation protocols for its range of candidate stem cell-based therapies.
As US FDA Commissioner Margaret Hamburg finishes her trip through India, the country is now shifting its focus to the regulation of stem cell and other cell therapies.
The new Centre for Cell Manufacturing Ireland (CCMI) in Galway means Ireland-based scientists will be able to manufacture culture-expanded stem cells for drug research for the first time.
Commercial-scale hES culturing is now a possibility thanks to a new technique that - the developers claim - resolves the ethical, technical and regulatory issues that have held back research.
Good news for stem cell scientists this week with new data indicating that patients support the use of induced pluripotent stem cells (iPSC) in biopharmaceutical research if proper consent is obtained.
Recent reports of a 'clinical trial' assessing 'stem cells' for the treatment of AMD are wrong say the Japanese researchers trying to transform somatic cells into retinal pigment epithelium (RPE) cells for transplant.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
The US FDA has published a 483 detailing the violations it observed during an inspection of stem cell firm Celltex Therapeutics in April and the document does not make for comfortable reading.
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
CellCura has inked an agreement with IDT Biologika for the testing and adaptation of its protein-free (PF) media for the production of cell lines for vaccine manufacturing.
CMO Angel Biotechnologies has called in UK-based engineering group WH Partnership to help re-commissioning its GMP standard biomanufacturing facility in Cramlington near Newcastle-upon-Tyne.
French contract research organisation (CRO) CIT will work on in vitro toxicity testing for pharmaceutical and cosmetic ingredients as the newest member of the European “ScreenTox” network.
Beta-Pro is addressing rising demands from drug discovery and research institutes in the hepatocyte market by expanding its site at the University of Virginia Research Park, US, with a new GLP facility.
Suzhou Erye, a subsidiary of NeoStem Pharmaceutical, has passed inspection by the Chinese Food and Drug Administration (SFDA) meaning the company's new manufacturing facility will go ahead with the manufacture of penicillin and cephalosporin powder...
New Synthemax synthetic growth matrix promises improved scalability for large-scale hESC production which, say developers Geron and Corning, will cut cost of cell therapy manufacture.
ISCO’s stem cell manufacturing facility has passed final building inspection, enabling it to implement the processes and cGMP standards needed to produce clinical-grade products.
Demand for downstream processing products from biotechs drove the continued recovery of Millipore’s bioprocessing division in Q2 but operating income remained flat.
